Gwendolyn Binder Scholl
About Gwendolyn Binder Scholl
Gwendolyn Binder Scholl serves as the Chief Technology Officer at Adaptimmune Us, where she leads efforts in T cell immunotherapy. With a background in molecular biology and immunology, she has held various leadership roles in the biotechnology sector, contributing to the development of innovative treatments for serious diseases.
Current Role at Adaptimmune
Gwendolyn Binder Scholl serves as the Chief Technology Officer at Adaptimmune since 2016. In this role, she leads the integration of research, manufacturing, and translational sciences to develop novel medicines targeting serious diseases. Scholl focuses on aligning discovery research with clinical and product development, particularly in T cell immunotherapy. Her leadership aims to establish the commercial availability of transformative T cell immunotherapy products for patients.
Previous Experience at Adaptimmune
Prior to her current position, Gwendolyn Binder Scholl worked at Adaptimmune as the Executive Vice President and Head of Translational Sciences from 2011 to 2016. During her tenure, she contributed to advancing the company’s research initiatives and played a significant role in the development of T cell immunotherapy strategies. Her work during this period laid the groundwork for her current responsibilities.
Professional Background at Virxsys and University of Pennsylvania
Before joining Adaptimmune, Scholl held the position of Scientific Coordinator at Virxsys from 2002 to 2005. She also served as the Director of Operations at the University of Pennsylvania from 2006 to 2011. In these roles, she gained experience in managing scientific operations and coordinating research efforts, which contributed to her expertise in the field of immunology and translational sciences.
Education and Expertise in Immunology
Gwendolyn Binder Scholl earned her Bachelor of Arts degree in Molecular Biology and Biochemistry from Wells College, completing her studies from 1992 to 1996. She furthered her education at The Johns Hopkins University School of Medicine, where she obtained a Doctor of Philosophy in Immunology and Medicine from 1996 to 2002. Her academic background provides a strong foundation for her work in T cell immunotherapy and translational research.
Strategic Contributions at Adaptimmune
As a member of the Executive Committee at Adaptimmune, Gwendolyn Binder Scholl contributes to strategic decision-making processes. Her insights and expertise help guide the company's direction in developing innovative therapies. Her role emphasizes the importance of integrating scientific research with clinical applications to enhance patient outcomes in immunotherapy.